7MARGOLIUS H S. Molecular characteristics and cellular and tissue responses[J]. Diabetes, 1996, 45( Suppl 1 ) : S14 - S19.
8MOMBOUL J V. ACE inhibition, endothelial function and coronary artery lesions: Role of kinins and nitric oxide[ J]. Drugs, 1997, 54(Suppl 5) : 12 -22.
9CONSENTINO F, LUSCHER T F. Endothelial dysfunction in diabetes mellitus[ J ]. J Cardiovasc Pharmacol, 1998, 32 ( Suppl 3 ) : S54 -61.
10MANTO A, COTRONEO P, PERCELL G, et al. Urinary kallikrein excretion in type Ⅰ (insulin -dependent) diabetes mellitus [J]. Diabetologia,1993,36(5):423-427.
1Drucker D, Nauck. M. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes[J]. The Lancet. 2006, 368(9548): 1696-1705.
2Roberge JN, Brubaker PL.. Regulation of intestinal proglucagon- derived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop [J]. Endocrinology, 1993, 133(1):233-240.
3MacDonald P.E.Wheeler M.B.Vohage- dependentK, channels inpancreatic betacells :Role; regulation and potential as therapeutic targem[ J ]. Diabetologia ;2003,46(8) : 1046--1062.
4MacDonaldP.E.HaXiaoFang.Wang Jing.Members of the Kv1 and Kv2 Voltage--Dependent K, Channel Families Regulate Insulin Secretion [J] .Molecular Endocrlnolcgy, 2001, 15 (8): 1423 --1435.
5Drucker D,Nauck. M. The incretin system: glucagon-likepeptide-1 eceptor agonists and dipeptidyl peptidase-4 inhibi-tors in type 2 diabetes [ J] . The ancet,2006, 368(9548) : 1696-1705.
